Brokerages Expect IDEAYA Biosciences (NASDAQ:IDYA) to Post -$0.57 Earnings Per Share

Wall Street analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to report ($0.57) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for IDEAYA Biosciences’ earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.63). IDEAYA Biosciences reported earnings of ($1.30) per share in the same quarter last year, which indicates a positive year over year growth rate of 56.2%. The business is scheduled to report its next quarterly earnings report on Monday, August 10th.

On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($2.53) to $2.30. For the next financial year, analysts expect that the business will post earnings of ($1.89) per share, with EPS estimates ranging from ($3.08) to $0.25. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.02).

Several analysts have issued reports on IDYA shares. Zacks Investment Research downgraded shares of IDEAYA Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 26th. BidaskClub upgraded shares of IDEAYA Biosciences from a “buy” rating to a “strong-buy” rating in a report on Friday. Roth Capital assumed coverage on shares of IDEAYA Biosciences in a report on Friday, March 13th. They issued a “buy” rating and a $12.00 price objective for the company. HC Wainwright boosted their target price on shares of IDEAYA Biosciences from $13.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Finally, ValuEngine raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. IDEAYA Biosciences currently has a consensus rating of “Buy” and a consensus target price of $19.45.

In other IDEAYA Biosciences news, CFO Paul A. Stone sold 3,100 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $17.97, for a total transaction of $55,707.00. Following the sale, the chief financial officer now directly owns 18,100 shares of the company’s stock, valued at $325,257. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Value Fund L. P. Biotechnology acquired 117,996 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $14.31 per share, for a total transaction of $1,688,522.76. Over the last ninety days, insiders have acquired 235,992 shares of company stock worth $3,377,408 and have sold 13,273 shares worth $190,783.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of IDEAYA Biosciences by 234.0% during the first quarter. BlackRock Inc. now owns 38,218 shares of the company’s stock valued at $158,000 after purchasing an additional 26,774 shares during the last quarter. Alambic Investment Management L.P. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $148,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $151,000. 49.87% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ IDYA traded up $0.96 during trading on Thursday, hitting $14.21. The company had a trading volume of 520,493 shares, compared to its average volume of 588,267. The company has a market cap of $294.16 million and a P/E ratio of -4.72. IDEAYA Biosciences has a 52 week low of $2.95 and a 52 week high of $19.97. The business’s 50-day moving average is $9.78 and its 200 day moving average is $7.47. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.18 and a current ratio of 12.18.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Featured Article: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.